4886.T
ASKA Pharmaceutical Holdings Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 2,071.00
−0.10%Year over year
Reported trailing growth
- Revenue
- +10.9%
- EBITDA
- —
- EBIT
- +9.4%
- EPS
- +6.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -0.2%
- EBITDA
- —
- EPS
- -7.8%
Three-year CAGR
- Revenue
- +5.6%
- EBITDA
- +2.0%
- EBIT
- +4.5%
- Net income
- +8.6%
- EPS
- +8.4%
- Free cash flow
- +9.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026